08:00 , Nov 13, 2006 |  BioCentury  |  Strategy

Biomira chronicles

Biomira chronicles Weekly stock price for Biomira (TSX:BRA; BIOM) on the Toronto exchange tracked against selected events since 2000. A. 6/29/00 - BRA reacquires rights to Theratope breast cancer vaccine from Chiron, which obtained co-development...
07:00 , Apr 2, 2001 |  BC Week In Review  |  Company News

Biomira, Biovector Therapeutics SA deal

The companies terminated a 1998 co-development deal for BIOM's idiotypic vaccine against B cell lymphoma (see BioCentury, Sept. 28, 1998). BIOM said Biovector made a decision to focus on developing its own programs following a...
08:00 , Mar 30, 2001 |  BC Extra  |  Company News

Biomira, Biovector terminate deal

Biomira (BIOM; TSE:BRA) and Biovector Therapeutics (Toulouse, France) terminated a co-development deal for BIOM's idiotypic vaccine against B cell lymphoma. BIOM said the termination resulted from Biovector's decision to focus on developing its own drug...
08:00 , Jan 22, 2001 |  BC Week In Review  |  Company News

Epimmune management update

Epimmune Inc. (EPMN), San Diego, Calif.   Business: Cancer, Infectious diseases   Hired: Emile Loria as president, CEO and a director, formerly president and CEO at Biovector Therapeutics S.A.  ...
08:00 , Jan 18, 2001 |  BC Extra  |  Company News

Epimmune names new president, CEO

EPMN, a developer of cellular immunity vaccines for cancer and infectious diseases, hired Emile Loria as president, CEO and a director. Prior, he was president and CEO of vaccine company Biovector Therapeutics (Toulouse, France)....
07:00 , Aug 7, 2000 |  BC Week In Review  |  Clinical News

EradicAide HIV vaccine regulatory update

The University of Texas received European Patent No. 0671947 covering antiviral vaccines that elicit cytotoxic T lymphocyte (CTL) responses without eliciting an antibody response. BQST, the exclusive licensee of the patent, is developing its EradicAide...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Company News

Hybrigenics SA management update

Hybrigenics SA, Paris, France   Business: Enabling technology   Hired: Frederic Allemand as VP of business development and marketing, formerly VP of business development at Biovector Therapeutics SA  ...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Clinical News

Lipomel: Began Phase II trial

Biovector Therapeutics S.A., Toulouse, France   Product: Lipomel   Business: Cancer   Therapeutic category: Immune stimulation   Target: Immune cells   Description: Therapeutic vaccine using the MART melanoma antigen   Indication: Treat melanoma   Status:...
07:00 , Apr 17, 2000 |  BC Week In Review  |  Company News

BioQuest, Biovector deal

The companies will evaluate the development of an HIV vaccine that combines HIVX's cocktail of HIV protein envelope peptides with Biovector's technology for delivering antigens in lipopeptide constructs to induce cellular immune responses. HIVX is...
08:00 , Feb 22, 2000 |  BC Week In Review  |  Company News

BioChem, Biovector deal

The companies will develop a nasal vaccine against Streptococcus pneumoniae that combines BCHE’s protein antigen with Biovector’s Light Biovector Systems drug delivery technology. The vaccine is the second announced under the companies’ 1997 collaboration. A...